EBRCZ EBR Systems, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1347123 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-45.6%
TTM EPS YoY83.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin11.4%
Operating margin-737.5%
Net margin-774.5%
FCF margin-919.0%
EBITDA margin-726.4%
Returns
ROE-112.9%
ROA-51.7%
ROIC (approx.)-57.8%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets47.8%
Debt / equity0.54x
Current ratio2.11x
Interest coverage-11.50x
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio3.6%
Payout ratio—
Capex / revenue91.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.62M | — |
| Cost of revenue | $1.13M | — |
| Gross profit | $490,000 | — |
| R&D expense | $23.94M | $27.07M |
| SG&A expense | $22.64M | $11.25M |
| Operating income | -$46.09M | -$38.32M |
| Interest expense | $5.64M | $6.03M |
| Pretax income | -$48.76M | -$40.80M |
| Income tax | $2,000 | $2,000 |
| Net income | -$48.76M | -$40.80M |
| EBITDA | -$45.68M | -$37.73M |
| EPS (basic) | -0.12 | -0.13 |
| EPS (diluted) | -0.12 | -0.13 |
| Weighted avg. shares (diluted) | 417.33M | 325.00M |
| Banking | ||
| Net interest income | — | $3.18M |
| Balance sheet | ||
| Cash & equivalents | $5.79M | $6.92M |
| Short-term investments | $47.40M | $53.75M |
| Inventory | $13.79M | $1.39M |
| Current assets | $73.11M | $64.47M |
| PP&E, net | $5.48M | $795,000 |
| Total assets | $97.23M | $73.56M |
| Current liabilities | $14.05M | $8.33M |
| Long-term debt | $41.80M | $41.84M |
| Total debt | $41.80M | $41.84M |
| Total liabilities | $71.64M | $49.20M |
| Shareholders' equity | $25.59M | $24.36M |
| Net debt | $36.01M | $34.92M |
| Shares outstanding | 45.03M | 371.08M |
| Cash flow statement | ||
| Operating cash flow | -$53.19M | -$41.23M |
| Capital expenditure | $3.68M | $273,000 |
| Free cash flow | -$56.88M | -$41.50M |
| Investing cash flow | $7.84M | $1.11M |
| Financing cash flow | $46.83M | $32.48M |
| Depreciation & amortization | $403,000 | $587,000 |
| Stock-based compensation | $3.05M | $1.74M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.